Unichem Laboratories Ltd (UNICHEMLAB) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 270205,
    "name": "Unichem Labs.",
    "stock_name": "Unichem Labs.",
    "full_name": "Unichem Laboratories Ltd",
    "name_url": "stocks-analysis/unichem-labs",
    "exchange": 1,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "445.55",
    "chg": -4.45,
    "chgp": "-0.99%",
    "dir": -1,
    "prev_price": "450.00",
    "mcapval": "3,151.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 506690,
    "symbol": "UNICHEMLAB",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE351A01035",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "5.05 k",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/unichem-labs-270205-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Unichem Labs. Sees Revision in Market Evaluation Amidst Challenging Financial Trends",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/unichem-labs-downgraded-to-sell-by-marketsmojo-amid-weak-financial-and-technical-signals-3735304",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/UnichemLabs_mojoScore_3735304.png",
        "date": "2025-11-28 10:04:56",
        "description": "Unichem Labs., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting shifts in its financial and technical outlook. This adjustment follows a period marked by subdued financial performance and cautious market sentiment, underscoring the complexities faced by the company in the current environment."
      },
      {
        "title": "Is Unichem Labs. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-unichem-labs-technically-bullish-or-bearish-3696235",
        "imagepath": "",
        "date": "2025-11-13 08:13:03",
        "description": "As of 12 November 2025, the technical trend for Unichem Labs has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. Key indicators driving this include the daily moving averages indicating bearish momentum, and the weekly KST and Dow Theory both showing bearish signals. The MACD on a monthly basis is mildly bearish, while the Bollinger Bands also reflect a mildly bearish outlook. Despite some mildly bullish signals from the weekly MACD and OBV, the overall technical picture remains negative, particularly given the significant year-to-date decline of 35.14% compared to the Sensex's 8.10% gain...."
      },
      {
        "title": "Is Unichem Labs. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-unichem-labs-overvalued-or-undervalued-3696014",
        "imagepath": "",
        "date": "2025-11-13 08:08:16",
        "description": "As of 12 November 2025, the valuation grade for Unichem Labs. has moved from very attractive to attractive, indicating a shift in perception regarding its value. The company is currently assessed as undervalued, particularly in comparison to its peers. Key ratios include a PE ratio of 22.88, an EV to EBITDA of 14.21, and a PEG ratio of 0.05, which suggests strong growth potential relative to its price.\n\nIn the peer comparison, Unichem Labs. stands out against companies like Sun Pharma, which has a PE ratio of 35.94, and Cipla, with a PE ratio of 22.56. This positions Unichem Labs. favorably within the industry, especially considering its attractive valuation amidst peers that are deemed expensive. Despite recent stock performance lagging behind the Sensex over the past year, the long-term outlook remains positive, with a notable 5-year return of 105.39% compared to the Sensex's 94.82%...."
      },
      {
        "title": "Unichem Laboratories Faces Mixed Technical Trends Amid Market Challenges and Resilience",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/unichem-laboratories-technical-trend-shifts-from-mildly-bearish-to-bearish-amid-stock-decline-3696446",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/UnichemLaborato_technicaldot_3696446.png",
        "date": "2025-11-13 08:02:17",
        "description": "Unichem Laboratories, a small-cap pharmaceutical company, has faced significant challenges over the past year, with a notable decline in stock performance compared to the broader market. Despite recent technical indicators suggesting bearish sentiment, the company has shown resilience with strong long-term returns, indicating potential for strategic improvements."
      },
      {
        "title": "How has been the historical performance of Unichem Labs.?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-unichem-labs-3694589",
        "imagepath": "",
        "date": "2025-11-12 23:47:31",
        "description": "Answer:\nThe historical performance of Unichem Labs shows a significant recovery and growth in recent years, particularly in the fiscal year ending March 2025.\n\nBreakdown:\nUnichem Labs has experienced a steady increase in net sales, rising from 1,125.01 crore in March 2020 to 2,110.97 crore in March 2025. This growth is reflected in total operating income, which also increased from 1,125.01 crore to 2,110.97 crore over the same period. The company's total expenditure, excluding depreciation, rose from 1,263.54 crore in March 2019 to 1,846.11 crore in March 2025, yet the operating profit (PBDIT) improved significantly, reaching 300.18 crore in March 2025, compared to a loss of 7.04 crore in March 2023. Profit before tax turned positive at 154.59 crore in March 2025, recovering from a loss of 176.36 crore in March 2023, while profit after tax also saw a turnaround, achieving 137.52 crore in March 2025 after lo..."
      },
      {
        "title": "Unichem Laboratories Faces Mixed Technical Trends Amid Market Volatility",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/unichem-laboratories-technical-trend-shifts-from-bearish-to-mildly-bearish-amid-stock-price-increase-3691551",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/UnichemLaborato_technicaldot_3691551.png",
        "date": "2025-11-12 08:00:32",
        "description": "Unichem Laboratories, a small-cap pharmaceutical company, has experienced significant volatility, with its stock recently priced at 484.90. Over the past year, it has faced a notable decline, contrasting with the Sensex's modest gains. Technical indicators present a mixed outlook, reflecting caution amid fluctuating market dynamics."
      },
      {
        "title": "Are Unichem Labs. latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-unichem-labs-latest-results-good-or-bad-3690462",
        "imagepath": "",
        "date": "2025-11-11 19:33:22",
        "description": "Unichem Laboratories' latest financial results for Q2 FY26 reveal a complex operational landscape. The company reported net sales of ₹578.96 crores, reflecting a year-on-year growth of 14.11% and a quarter-on-quarter increase of 9.94%. However, this revenue growth did not translate into profitability, as the company recorded a net loss of ₹11.89 crores, a significant decline from a profit of ₹24.63 crores in the same quarter last year.\n\nThe operating margin showed some improvement, rising to 11.43% from 10.94% year-on-year, indicating better operational efficiency. Nonetheless, the profit before tax was negative at ₹10.82 crores, highlighting ongoing challenges in achieving profitability. The company's return on equity (ROE) remains low at 1.64%, and the return on capital employed (ROCE) averaged negative 1.08%, suggesting inefficiencies in capital utilization.\n\nInterest expenses surged to ₹8.24 crores, the..."
      },
      {
        "title": "Unichem Laboratories Q2 FY26: Losses Deepen Amid Operational Challenges",
        "link": "https://www.marketsmojo.com/news/result-analysis/unichem-laboratories-q2-fy26-losses-deepen-amid-operational-challenges-3690158",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/UnichemLaborato_quaterlyResult_3690158.png",
        "date": "2025-11-11 17:47:23",
        "description": "Unichem Laboratories Ltd. reported a consolidated net loss of ₹11.89 crores for Q2 FY26, marking the company's second consecutive quarter of losses and representing a sharp deterioration from a profit of ₹24.63 crores in the corresponding quarter last year. The Mumbai-based pharmaceutical manufacturer's stock plunged 5.10% following the results announcement, reflecting investor concerns over the company's operational challenges despite revenue growth of 14.11% year-on-year to ₹578.96 crores."
      },
      {
        "title": "Unichem Laboratories Hits New 52-Week Low at Rs. 438.5",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/unichem-laboratories-hits-new-52-week-low-at-rs-4385-3689888",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/UnichemLaborato_priceRelatedfactors_3689888.png",
        "date": "2025-11-11 13:42:18",
        "description": "Unichem Laboratories has reached a 52-week low of Rs. 438.5, despite showing some resilience by outperforming its sector. The stock peaked at Rs. 490.1 during intraday trading. Over the past year, it has faced significant challenges, with a notable decline in performance compared to the broader market."
      }
    ],
    "total": 525,
    "sid": "270205",
    "stock_news_url": "https://www.marketsmojo.com/news/unichem-laboratories-270205"
  },
  "announcements": [
    {
      "details": "Unichem Laboratories Limited has informed the Exchange regarding 'ANDA approval for Unichem's Buspirone Hydrochloride '.",
      "source": "NSE",
      "caption": "Unichem Laboratories Limited - Updates",
      "datetime": "18-Nov-2019"
    },
    {
      "details": "Unichem Laboratories Limited has informed the Exchange regarding Disclosure on Related Party transactions for half year ended September 30, 2019.",
      "source": "NSE",
      "caption": "Unichem Laboratories Limited - Other General Purpose",
      "datetime": "15-Nov-2019"
    },
    {
      "details": " <table><tr><td>Unichem Laboratories Limited has informed the Exchange regarding 'USFDA approval for the Company's plant at Kolhapur'. </td></tr></table>",
      "source": "NSE",
      "caption": "Updates",
      "datetime": "20-Sep-2019"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Unichem Laboratories Ltd has declared <strong>200%</strong> dividend, ex-date: 01 Aug 22",
          "dt": "2022-08-01",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Unichem Laboratories Ltd has announced <strong>2:5</strong> stock split, ex-date: 21 Oct 10",
          "dt": "2010-10-21",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Unichem Labs. Sees Revision in Market Evaluation Amidst Challenging Financial Trends

2025-11-28 10:04:56

Unichem Labs., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting shifts in its financial and technical outlook. This adjustment follows a period marked by subdued financial performance and cautious market sentiment, underscoring the complexities faced by the company in the current environment.

Is Unichem Labs. technically bullish or bearish?

2025-11-13 08:13:03

As of 12 November 2025, the technical trend for Unichem Labs has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. Key indicators driving this include the daily moving averages indicating bearish momentum, and the weekly KST and Dow Theory both showing bearish signals. The MACD on a monthly basis is mildly bearish, while the Bollinger Bands also reflect a mildly bearish outlook. Despite some mildly bullish signals from the weekly MACD and OBV, the overall technical picture remains negative, particularly given the significant year-to-date decline of 35.14% compared to the Sensex's 8.10% gain....

Is Unichem Labs. overvalued or undervalued?

2025-11-13 08:08:16

As of 12 November 2025, the valuation grade for Unichem Labs. has moved from very attractive to attractive, indicating a shift in perception regarding its value. The company is currently assessed as undervalued, particularly in comparison to its peers. Key ratios include a PE ratio of 22.88, an EV to EBITDA of 14.21, and a PEG ratio of 0.05, which suggests strong growth potential relative to its price. In the peer comparison, Unichem Labs. stands out against companies like Sun Pharma, which has a PE ratio of 35.94, and Cipla, with a PE ratio of 22.56. This positions Unichem Labs. favorably within the industry, especially considering its attractive valuation amidst peers that are deemed expensive. Despite recent stock performance lagging behind the Sensex over the past year, the long-term outlook remains positive, with a notable 5-year return of 105.39% compared to the Sensex's 94.82%....

Unichem Laboratories Faces Mixed Technical Trends Amid Market Challenges and Resilience

2025-11-13 08:02:17

Unichem Laboratories, a small-cap pharmaceutical company, has faced significant challenges over the past year, with a notable decline in stock performance compared to the broader market. Despite recent technical indicators suggesting bearish sentiment, the company has shown resilience with strong long-term returns, indicating potential for strategic improvements.

How has been the historical performance of Unichem Labs.?

2025-11-12 23:47:31

Answer: The historical performance of Unichem Labs shows a significant recovery and growth in recent years, particularly in the fiscal year ending March 2025. Breakdown: Unichem Labs has experienced a steady increase in net sales, rising from 1,125.01 crore in March 2020 to 2,110.97 crore in March 2025. This growth is reflected in total operating income, which also increased from 1,125.01 crore to 2,110.97 crore over the same period. The company's total expenditure, excluding depreciation, rose from 1,263.54 crore in March 2019 to 1,846.11 crore in March 2025, yet the operating profit (PBDIT) improved significantly, reaching 300.18 crore in March 2025, compared to a loss of 7.04 crore in March 2023. Profit before tax turned positive at 154.59 crore in March 2025, recovering from a loss of 176.36 crore in March 2023, while profit after tax also saw a turnaround, achieving 137.52 crore in March 2025 after lo...

Unichem Laboratories Faces Mixed Technical Trends Amid Market Volatility

2025-11-12 08:00:32

Unichem Laboratories, a small-cap pharmaceutical company, has experienced significant volatility, with its stock recently priced at 484.90. Over the past year, it has faced a notable decline, contrasting with the Sensex's modest gains. Technical indicators present a mixed outlook, reflecting caution amid fluctuating market dynamics.

Are Unichem Labs. latest results good or bad?

2025-11-11 19:33:22

Unichem Laboratories' latest financial results for Q2 FY26 reveal a complex operational landscape. The company reported net sales of ₹578.96 crores, reflecting a year-on-year growth of 14.11% and a quarter-on-quarter increase of 9.94%. However, this revenue growth did not translate into profitability, as the company recorded a net loss of ₹11.89 crores, a significant decline from a profit of ₹24.63 crores in the same quarter last year. The operating margin showed some improvement, rising to 11.43% from 10.94% year-on-year, indicating better operational efficiency. Nonetheless, the profit before tax was negative at ₹10.82 crores, highlighting ongoing challenges in achieving profitability. The company's return on equity (ROE) remains low at 1.64%, and the return on capital employed (ROCE) averaged negative 1.08%, suggesting inefficiencies in capital utilization. Interest expenses surged to ₹8.24 crores, the...

Unichem Laboratories Q2 FY26: Losses Deepen Amid Operational Challenges

2025-11-11 17:47:23

Unichem Laboratories Ltd. reported a consolidated net loss of ₹11.89 crores for Q2 FY26, marking the company's second consecutive quarter of losses and representing a sharp deterioration from a profit of ₹24.63 crores in the corresponding quarter last year. The Mumbai-based pharmaceutical manufacturer's stock plunged 5.10% following the results announcement, reflecting investor concerns over the company's operational challenges despite revenue growth of 14.11% year-on-year to ₹578.96 crores.

Unichem Laboratories Hits New 52-Week Low at Rs. 438.5

2025-11-11 13:42:18

Unichem Laboratories has reached a 52-week low of Rs. 438.5, despite showing some resilience by outperforming its sector. The stock peaked at Rs. 490.1 during intraday trading. Over the past year, it has faced significant challenges, with a notable decline in performance compared to the broader market.

View All News